Kai P. Huang
Berlin, BE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
[68Ga] labelled Exendin for radioguided surgery of intrapancreatic insulin producing lesions in patients with congenital hyperinsulinism.
Journal: EJNMMI research
Published: September 02, 2024
Dosimetric analysis of a compartmental model for radioligand uptake in tumor lesions.
Journal: Biomedical physics & engineering express
Published: March 29, 2023
Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT.
Journal: Pharmaceutics
Published: May 18, 2022
Prognostic Value of the Largest Lesion Size for Progression-Free Survival in Patients with NET Undergoing Salvage PRRT with [177Lu]Lu-DOTATOC.
Journal: Cancers
Published: February 21, 2022
Correlation Between Quantitative PSMA PET Parameters and Clinical Risk Factors in Non-Metastatic Primary Prostate Cancer Patients.
Journal: Frontiers in oncology
Published: February 18, 2022
Sentinel Lymph Node Biopsy in Early Stages of Oral Squamous Cell Carcinoma Using the Receptor-Targeted Radiotracer 99mTc-Tilmanocept.
Journal: Diagnostics (Basel, Switzerland)
Published: June 06, 2021
The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [177Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis.
Journal: Cancers
Published: January 19, 2021
Shortened Tracer Uptake Time in GA-68-DOTATOC-PET of Meningiomas Does Not Impair Diagnostic Accuracy and PET Volume Definition.
Journal: Diagnostics (Basel, Switzerland)
Published: November 24, 2020
18F-sodium fluoride bone deposition quantitation with PET in Mice: Variation with age, sex, and circadian rhythm.
Journal: Nuklearmedizin. Nuclear medicine
Published: July 17, 2020
In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2nd Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With 177Lu-PSMA.
Journal: Frontiers in oncology
Published: June 30, 2020
Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with 177Lu-labeled prostate-specific membrane antigen.
Journal: Annals of nuclear medicine
Published: June 02, 2020
Last Updated: 09/26/2026